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ABSTRACT
Breast cancer remains the leading cause of death among women, and there is 
a need to develop minimally invasive marker. Our previous study based on 
clinicopathological profile in pre-chemotherapy patients showed upregulation of 
miR-21, 1.32 folds higher at advanced stage compared to early stage. Therefore, 
the patients were used as post-chemotherapy samples. The aim of this research is 
to examine the expression of miR-21-5p as potential marker to assess the response 
of adjuvant chemotherapy in breast cancer patients. The samples were collected 
using cross sectional method, with total 39 blood plasma samples from breast 
cancer patients receiving adjuvant chemotherapy and 12 healthy control samples. 
Plasma was obtained from blood samples and RNA isolation was performed. Total 
RNA was reverse-transcribed using cDNA synthesis. The expression of miR-21-5p 
was then analyzed using specific primer for miR-21-5p, while miR-16 was used 
as the reference gene. Livak Method was used to calculate the expression level 
in each group. The result showed that there is significantly decreased expression 
of miR-21-5p in post-chemotherapy patients, as much as 2.61 folds compared 
to pre-chemotherapy (p<0.05). The expression of miR-21-5p was 2.2 folds 
higher (p<0.05) in pre-chemotherapy group compared to healthy control, while 
its expression was 0.8 folds higher (p<0.05) in post-chemotherapy compared to 
healthy control. In conclusion, miR-21-5p might be used as marker for adjuvant 
chemotherapy response in breast cancer, due to its significantly different expressions 
found between pre-chemotherapy, post-chemotherapy, and healthy control. The 
research on analysis of the expression of tumor suppressor protein regulated by 
miR-21-5p might be required in near future.
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